Abstract submissions for paper presentations and posters for the 43rd World Hospital Congress of the International Hospital Federation will be closing on 15 February. Hospitals and health service providers interested in showcasing their innovations, best practices and outstanding programs to the international community are encouraged to submit their abstracts now.
The World Hospital Congress is a unique global forum that brings together leaders of national and international hospital and healthcare organizations to share knowledge, expertise, experiences and best practices in leadership in hospital and healthcare management and delivery of services.
The 2019 World Hospital Congress, hosted by the Ministry of Health of the Sultanate of Oman, has the over-arching theme “People at the heart of health services in peace and crisis”.
Abstracts have to be submitted online at https://congress.ihf-fih.org/ihf_abstracts by 15 February (11:59pm UTC -11). Abstracts for the following sub-themes can be put forward:
Resilient health services:
Best practices for preparedness and responses to disasters, outbreaks and cyberattacks
Mitigating consequences of conflicts and terror attacks to continue serving all especially vulnerable groups
Operating under severe resource constraints
Leading practices reflecting systematic approaches to learning from crises and trauma
Violence in the workplace
Health investment for prosperity
Exploring governance practices driving better efficiency and relevance
What management and leadership can do for increased efficiency and outcomes
Inter-professional leadership for cost effectiveness and quality improvement
What are the impacts of hospitals in the local and national economy
Future of hospitals in an economically constrained world
Innovation for health impact
Removing barriers to innovation with change management
Hospital Technology Assessment to speed up innovation adoption
Embedding collaboration with industries for health innovation
Procurement to accelerate and develop innovation
Enhancing digital health services in the virtual space
More information including the submission process, general criteria and terms and conditions for presentersare available at https://congress.ihf-fih.org/ihf_abstracts
For any questions, contact congress@ihf-fih.org or visit www.worldhospitalcongress.org.
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:35:552020-08-26 14:36:032019 World Hospital Congress: Call for abstracts closes on 15 February
The 34th Korea International Medical and Hospital Equipment show held in Seoul last March gathered 1,313 exhibiting companies from 34 countries, including 649 domestic Korean manufacturers over 40,122 sq m of exhibition space. The 4-day event attracted over 73,000 visitors from 92 countries. About 30,000 items of medical equipment, including high tech devices, medical information systems, rehabilitation equipment and healthcare supplies were presented at the show. Over the years, KIMES has succeeded in establishing itself as the leading technology-oriented and most prominent medical exhibition in the whole of the South East Asian region. In tune with this year‘s theme ‘Think the Future’, a number of exhibitors, mostly domestic, were involved in robotic solutions applied to healthcare, showing a variety of robotic medical devices, for example medical sterilization robots, artificial joint orthopedic surgery robots, walking assistance robots as well as robotic rehabilitation systems. There was even a special rehabilitation robot booth in Hall B. For the third consecutive edition of the show, the Global Bio & Medical Plaza organized by KOTRA (Korea Trade Investment Promotion Agency) provided extra business opportunities for domestic exhibitors by helping to develop commercial and business relationships between foreign and overseas guests and Korean companies. KIMES is a definite must for international buyers interested in the latest product developments from the particularly dynamic and innovative Korean medical device industry as well as for foreign companies keen to boost their market share in the Korean growing healthcare industry fuelled by increasing consumer demand. KIMES 2019 will take place in Seoul from 14 to 17 March of next year.
KIMESwww.kimes.kr
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:35:552020-08-26 14:36:10KIMES 2018 : the Korean trade show previews the future of medical devices and technology
Playing an adventure video game featuring a fictitious, young emergency physician treating severe trauma patients was better than text-based learning at priming real doctors to quickly recognize the patients who needed higher levels of care, according to a new trial led by the University of Pittsburgh School of Medicine. The results held even though doctors assigned to the game enjoyed it less than those assigned to traditional, text-based education. This indicates that if game enjoyment can be improved, the already favourable results might be enhanced. “Physicians must make decisions quickly and with incomplete information. Each year, 30,000 preventable deaths occur after injury, in part because patients with severe injuries who initially present to non-trauma centres are not promptly transferred to a hospital that can provide appropriate care,” said lead author Deepika Mohan, M.D., M.P.H., assistant professor in Pitt’s departments of Critical Care Medicine and Surgery. “An hour of playing the video game recalibrated physicians’ brains to such a degree that, six months later, they were still out-performing their peers in recognizing severe trauma.” Mohan created the game Night Shift with Schell Games, a Pittsburgh-based educational and entertainment game development company. The game is designed to tap into the part of the brain that uses pattern recognition and previous experience to make snap decisions using subconscious mental shortcuts – a process called heuristics. Physicians in non-trauma centres typically see only about one severe trauma per 1,000 patients. As a result, their heuristic abilities can become skewed toward obvious injuries such as gunshot wounds, and miss equally severe traumas such as internal injuries from falls. On average, 70 percent of severely injured patients who present to non-trauma centres are under-triaged and not transferred to trauma centres as recommended by clinical practice. Both the game and the text-based learning are intended to help physicians improve their decision making regarding severe traumas. The game, however, sought to do this through narrative engagement, or the use of stories to promote behaviour change, which has shown promise in recalibrating heuristics. Mohan’s team recruited 368 emergency medicine physicians from across the country who did not work at hospitals with trauma specialization. Half were assigned to play the game and half were asked to spend at least an hour reading the educational materials. Participants then responded to questionnaires and completed a simulation that tested how often they “under-triaged,” or failed to send severe trauma patients to hospitals with the resources necessary to handle them. Physicians who played the game under-triaged 53 percent of the time, compared with 64 percent for those who read the educational materials. Six months later, Mohan reassessed the physicians and found that the effect of the game persisted, with those who played the game under-triaging 57 percent of the time, compared to 74 percent for those who had read the educational materials.
UPMChttps://tinyurl.com/y9rlhcu3
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:35:552020-08-26 14:36:17Video game improves doctors’ recognition and triage of severe trauma patients
Hologic, Inc. opened on March 21, 2019 its first Learning and Experience Centre in Zaventem, Belgium (a municipality neighboring Brussels). The state-of-the-art facility provides comprehensive training for customers, healthcare professionals and employees across Hologic’s Europe, Middle East and Africa (EMEA) region, centralizing the education experience for Hologic’s technologies. Radiologists, lab technicians, obstetrician-gynecologists and many other healthcare professionals count on Hologic solutions to perform when lives are at stake. The 1,500m2 Learning and Experience Centre contains fully equipped training labs with demonstration capabilities for technologies from all four of Hologic’s divisions (Breast & Skeletal Health, Diagnostic, Gynecological Surgical and Medical Aesthetics) to ensure the highest level of understanding and provide hands-on experience. “The opening of our new Hologic Learning and Experience Centre in Brussels is a significant milestone in our company’s history and reflects our deep commitment to providing unparalleled training and support to our customers,” said Jan Verstreken, Regional President EMEA and Canada at Hologic. “Hologic is a global champion for women’s health and brings leading-edge technology to healthcare systems around the world. The patient is our greatest priority and when their health is in question, nothing is more important to us than providing the most accurate, effective, and timely diagnosis or treatment. As Hologic continues to gain recognition as a leader in women’s health, we commit to supporting the healthcare systems and their patients by ensuring the absolute best use of our truly unique technologies, for the direct benefit of millions of patients in the region.” For the first time, Hologic will bring training and education for all its products under one roof – located at the heart of Europe – to offer the most cohesive, convenient and interconnected experience. Products featured at the Hologic Learning and Experience Centre include: 3Dimensions™, a mammography system that delivers the fastest, highest resolution 3D™ images and is clinically proven to be more comfortable and enhance workflow; Panther Fusion®, a fully automated, integrated molecular testing platform with true sample-to-result automation, adaptable workflow options, and a consolidated testing menu; NovaSure®, a minimally invasive, one-time, five-minute endometrial ablation procedure to reduce or stop abnormal uterine bleeding; PicoSure®, a laser workstation to remove tattoos and revitalize skin by reducing the appearance of wrinkles, acne scars and pigment-like freckles, sunspots and discoloration. The creation of Hologic’s European hub and the consolidation of key European functions, including customer service, will create up to 60 new jobs in Belgium over the next 12 months. Each year, the new Learning and Experience Centre is expected to welcome several thousand visitors including healthcare professionals, key opinion leaders, current and prospective customers, distributor partners, and employees.
www.hologic.com
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:35:552020-08-26 14:35:58Hologic opens state-of-the-art learning and experience centre at the heart of Europe
Founded in 1983, CARS has played a leading role in medical and imaging informatics for more than 30 years by focusing on research and development on novel algorithms and systems and their applications in radiology and surgery. Recent successful CARS congresses have taken place in Barcelona, Berlin, Paris, Tokyo, San Francisco, London, Chicago, Osaka, Geneva, Pisa, Fukuoka, and Heidelberg. CARS 2019 will take place from June 18 to June 21, 2019 in Rennes, one of the leading cities for medical research and development in France, in the very special historic setting of the Couvent des Jacobins Convention Center. Main themes of CARS congresses include Medical Imaging, Computed Maxillofacial Imaging, Image Processing and Visualization, PACS and IHE, Telemedicine and E-Health, Computer Aided Diagnosis, Computer Assisted Radiation Therapy, Image and Model Guided Therapy, Personalized Medicine, Surgical Navigation, Surgical Robotics and Instrumentation, Surgical Simulation and Education, Computer Assisted Orthopaedic and Spinal Surgery, Computer Assisted Head and Neck, and ENT Surgery, Image Guided Neurosurgery, Minimally Invasive Cardiovascular and Thoracoabdominal Surgery, Information Processing in Computer-Assisted Intervention, Digital Operating Room, Human-Machine Interface, Pathology Informatics, Integrated Patient Care, Tumor Boards, Innovative Clinical Investigations. For more information on the 2019 event please visit our website or contact us by email at office@cars-int.org.
https://www.cars-int.org
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:35:552020-08-26 14:36:05CARS 2019 Computer Assisted Radiology and Surgery
Common beliefs and misconceptions in the community about dementia are still proving obstacles to treatment despite a rise in public awareness campaigns, Researchers from Flinders University in South Australia pooled the results of 32 dementia surveys from around the world published between 2012 and 2017 and found that public awareness of the causes of dementia has not changed. Almost half of the total 36,519 respondents had the common misconception that dementia was a normal part of ageing and was not preventable. The importance of formal educational attainment and management of cardiovascular were acknowledged by less than half of respondents even though regular exercise has been proven as the single most powerful influencer of brain health. The public also tended to endorse poorly supported risk reduction strategies such as taking vitamin supplements, ahead of more effective but time consuming and energetic strategies, such as exercise regimes. “We were surprised to find that dementia literacy is still so poor, given how much effort has been put into improving understanding,” said lead researcher Monica Cations. “The view that dementia is a normal part of ageing with few treatment options is a demonstrated barrier to both preventive health behaviours and to help-seeking and diagnosis in the event that symptoms emerge.” The 32 surveys were sourced from Europe(12), the United States (11), Asia (7) and Australia (2). The findings and associated problems are outlined in the paper, What does the general public understand about prevention and treatment of dementia? A systematic review of population-based surveys, which has been published by PlosOne. There are about 47 million people living with dementia worldwide. While research has not yet discovered a cure, there is accumulating evidence about the potential to prevent approximately one third of cases of dementia with management of risk factors such as poor educational attainment, hypertension, and depression. The recently adopted World Health Organization (WHO) Global Action Plan on Dementia urges all countries to implement campaigns to raise awareness about dementia. The plan includes a global target that all member countries will have at least one public awareness campaign on dementia by 2025.
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0196085http://theleadsouthaustralia.com.au/category/industries/health/
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:35:552020-08-26 14:36:12Study finds greater public awareness still needed about dementia
Researchers developed a new digital stethoscope that combines precision sensors, electrocardiogram technology and machine learning applications into one piece of equipment to better detect heart ailments and problems that might occur with an implanted heart pump. Jason Kolodziej and Steven Day, engineering professors at Rochester Institute of Technology, worked with Dr. Karl Schwarz, cardiologist and professor of medicine at the University of Rochester Medical Center, to develop an Advanced Digital Stethoscope prototype (pictured above). The researchers expanded capabilities and functions of a traditional stethoscope to detect off-rhythms of the heart, primarily one with an embedded left ventricular assist device, or heart pump. Left ventricular assist devices (LVAD) are used to help manage end-stage heart failure, pumping blood from the left ventricle to the aorta to provide needed blood flow for patients with severely reduced heart function. The research team determined that natural heart sounds and the sounds of the implanted LVAD may hold the key to diagnosing patients with suspected device dysfunction. “This stethoscope that we designed integrates multiple sensors into one. It is not necessarily a new sensor that measures something never measured before; it is something that in a hospital setting would be done by multiple machines. Most cardiologists aren’t wheeling around this data collection hardware,” said Kolodziej, associate professor of mechanical engineering in RIT’s Kate Gleason College of Engineering. Cardiovascular disease is one of the leading causes of death in the U.S. with more than 600,000 dying of heart disease annually, according to the Center for Disease Control. Diagnosis of the disease entails performing several important tests and assessments including ECG, echocardiograms, X-rays and cardiac magnetic resonance imaging, for example. Acoustic information through a stethoscope is also one means to attain information about heart function. The new design includes a microphone for recording data collected through the stethoscope, combined with ECG leads—stainless steel contact pads that would normally be affixed to a patient’s chest, arms and legs. Usually the ECG leads are part of a separate piece of equipment standard in acquiring digital audio of heart sounds. Instead, researchers attached them to the new stethoscope head. The new leads were 3D-printed at The Construct, an RIT laboratory. Apart from hardware for the project, computer algorithms—also referred to as machine learning techniques—are incorporated into the larger system to take in signals, and to learn and recognize defects. Techniques to improve acoustic diagnostics include spectral analysis, advanced automated neural networks and a combination of smartphone-based, interactive software that will allow the clinician to make a diagnosis when integrating the advanced acoustic analyses with other routine clinical information. Improvements to digital stethoscopes provide more information in the acoustic signature than is normally being used, and having been trained to listen for different things, physicians hear signals such as heart murmurs, valve regurgitation and other signals that indicate different defects, Day explained further. “It is almost unconscious, like people listening to engines, and hear something off that could mean a problem. But if you ask what sounds different, they may not be able to explain it or articulate it, but they just know. This is about getting the device to do that, to hear sounds and then to make that determination of what the problem could be,” said Day, a professor and head of RIT’s biomedical engineering program. He also has vast experience in the development of LVADs, building a state-of-the-art implantable blood pump with peers from the University of Virginia, the Utah Artificial Heart Institute and MedQuest Inc.
University of Rochester Medical Center https://tinyurl.com/y8ezqvo8
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:35:552020-08-26 14:36:00Researchers combine technologies to develop new digital stethoscope design
In the last few decades, dozens of new breast cancer drugs — from chemotherapies to targeted compounds — have become available for clinical use, and mammogram technology has gone from film to digital. But are the changes making a difference in how many women die of breast cancer? The answer to that question is a resounding yes, according to a multi-institutional network of researchers who have modelled the effect of breast cancer screening and treatment on mortality rates. The researchers’ models showed that screening and treatment reduced breast cancer mortality by 49 percent in 2012, compared with 37 percent in 2000. “These numbers represent very positive news for breast cancer patients,” said Sylvia Plevritis, PhD, professor of radiology and of biomedical data science at the Stanford University School of Medicine and lead author of the paper. “Advances in screening and treatment are saving patients’ lives, and this paper quantifies just how much of a difference these advances are making.” In 2005, Plevritis and her colleagues in the Cancer Intervention and Surveillance Modeling Network used data from 1975 through 2000 to reveal the relative contributions of screening and treatment to reductions in breast cancer mortality rates. Using knowledge of how breast cancer advances, they developed models representing how many women would die of the cancer with no screening and no treatments, then simulated the effect of screening and treatment on those mortality numbers. The decrease in mortality from the modelled baseline, they found, was about 50 percent due to screening and 50 percent due to treatment. “Now, over 10 years later, a lot has happened in the field,” said Plevritis, who heads the Stanford Center for Cancer Systems Biology. “We’ve moved from film-based mammography to digital; there are new molecularly targeted treatments and new types of chemotherapy regimens. We wondered whether these advances had changed the relative contributions of treatment and screening on breast cancer mortality.” Advances in screening and treatment are saving patients’ lives, and this paper quantifies just how much of a difference these advances are making. So researchers in the network updated their models to reflect molecular subtypes of breast cancer. Six independent teams — including researchers from Stanford, the Dana-Farber Cancer Institute, Erasmus Medical Center, Georgetown University Medical Center, Albert Einstein College of Medicine, the University of Wisconsin, Harvard Medical School and MD Anderson Comprehensive Cancer Center — put together models representing the effect of current treatment and screening. The group added new data — spanning 2000 to 2012 — to the existing data and compared the conclusions of each model, calculating average effects on mortality of screening and of treatments, including chemotherapy, hormone therapy and the drug trastuzumab, which targets an epidermal growth factor receptor, ERBB2, overexpressed in some tumours. By comparing six models, the researchers were able to replicate the analysis, making the team more confident in results that were seen in all the models. Not only did they look at the effects on breast cancer as a whole, but on molecular subtypes of breast cancer, such as those that are ER positive, meaning that they grow in response to the hormone ostrogen. “This time around, it was important to look at molecular subtypes because more women are being treated based on the molecular subtype of their tumour,” Plevritis said. The researchers found that in 2012, screening and treatment together reduced breast cancer mortality by 49 percent. For all breast cancers together, 37 percent of that reduction was due to screening, and 63 percent was due to treatment. However, when they looked at some molecular subtypes of cancer, the numbers varied. For ER-positive/ERBB2-positive cancer, the most common type and the type for which the greatest number of new targeted treatments are available, only 31 percent of the mortality decline was associated with screening, with 69 percent associated with treatment. For ER-negative/ERBB2-negative cancer, which has fewer treatment options, 48 percent of the mortality decline was associated with screening and 52 percent with treatment, similar to results from 2000. “Newer drugs, particularly ones that are molecularly targeted, are associated with a greater reduction in breast cancer mortality than screening,” said Jeanne Mandelblatt, MD, MPH, professor of oncology and of medicine at Georgetown University and a senior author of the paper. “However, screening is still having a significant effect in reducing breast cancer deaths.” In particular, the researchers pointed out, screening can lead to cancer detected at earlier stages and therefore less-intense treatments. Aside from reducing mortality rates, this can translate into fewer side effects and patient co-morbidities.
Stanford Medicinehttps://tinyurl.com/y87wczhd
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:35:552020-08-26 14:36:08New treatments, screening methods dramatically reduce breast cancer deaths
A new way of seeing when heavy wound scars are forming, and providing doctors the chance to intervene, has been developed by scientists from Nanyang Technological University, Singapore (NTU Singapore) and Northwestern University in the United States. Clinicians currently find it difficult to predict how scars will develop following surgery or after a burn wound, without resorting to invasive testing. Using new nanoparticles, the joint research team has shown in animals and human skin samples the potential to quickly and accurately predict whether a wound is likely to lead to excessive scarring as occurs in keloids and skin contractures. If necessary, doctors can then take conventional preventive measures to reduce scar formation, such as using silicon sheets to keep a wound flat and moist. In developed countries alone, about 100 million patients will form scars annually, arising from 80 million elective and trauma surgery operations. In Singapore, an estimated 400,000 people (1 in 12 people undergoing procedures) develop scars each year due to surgery. Excessive scarring can dramatically affect a patient’s quality of life, both physically and psychologically, as the scars can impede movement and activity, and can be painful when stretched The new technique was developed by a team led by Assistant Professor Xu Chenjie from NTU’s School of Chemical and Biomedical Engineering, nanoscience expert Professor Chad A Mirkin from Northwestern University, United States, and Dr Amy S Paller, Chair of Dermatology at Northwestern University Feinberg School of Medicine. The new detection method uses thousands of nanoparticles called NanoFlares, which have DNA strands attached to their surfaces like a ball of spikes. These nanoparticles are applied to closed wounds using a cream. After the nanoparticles have penetrated the skin cells for 24 hours, a handheld fluorescence microscope is used to look for signals given out by the nanoparticles’ interaction with target biomarkers inside the skin cells. If fluorescence signals are detected, they indicate abnormal scarring activity and preventive action can be taken to hopefully avoid heavier scarring. Currently, apart from the visual examination of mature scars, the only other tool to detect skin diseases accurately is to perform a biopsy, where a skin tissue sample is extracted and sent for laboratory testing. These biopsies may be painful and inconvenient for patients, as an open wound also risks infections and needs sutures which must be removed later Assistant Professor Xu Chenjie said: “When our bioengineered nanoparticles are applied on the skin, they will penetrate up to 2mm below the skin surface and enter scar cells.” “Upon binding with a specific tell-tale gene released by the scar cells, smaller DNA spikes are knocked loose and light up under the microscope like little light flares. The more flares we see, the more scarring activity there is.” These NanoFlares are made by coating Northwestern’s patented gold nanoparticles with tiny DNA strands targeting particular genes. It has shown negligible toxicity or side effects when tested on mice, rabbits and on human skin samples. Dr Amy S Paller, who is also the Director of Northwestern University Skin Disease Research Centre, said: “Beyond clinical observation, the gold standard for both clinical diagnosis and translational research of skin disorders is a biopsy. “This technology is an exciting first step towards having a non-invasive way to detect increases or decreases in gene expression. NanoFlares may prove to be a new tool to facilitate sub-phenotyping of disease based on expression patterns and leveraging gene expression changes as a sensitive way to detect early treatment responses.”
Nanyang Technology University media.ntu.edu.sg/NewsReleases/Pages/newsdetail.aspx?news=858001b3-7530-442a-a728-4e6abc115539
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:35:552020-08-26 14:36:15New nanoparticles help to detect serious scarring of wounds
In one of the most ambitious collaborative initiatives ever undertaken by the pharmaceutical industry, more than 20 leading biopharmaceutical companies in early July announced the launch of the AMR Action Fund, a ground-breaking partnership that aims to bring two to four new antibiotics to patients by 2030. These new treatments are urgently needed to address the rapid rise of antibiotic-resistant infections – or antimicrobial resistance (AMR).
The companies have raised so far nearly US$1 billion to support clinical research of innovative new antibiotics that address the most resistant bacteria and life-threatening infections. Through the AMR Action Fund, pharmaceutical companies will join forces with philanthropies, development banks, and multilateral organizations to strengthen and accelerate antibiotic development. The Fund will focus on urgent public health needs. It will provide much needed financial resources, as well as important technical support to help biotech companies bring novel antibiotics to patients.
The AMR Action Fund, an initiative of the international body representing the R&D pharmaceutical industry (International Federation of Pharmaceutical Manufacturers & Associations, IFPMA), was announced at simultaneous virtual launch events in Berlin, Germany, and Washington, D.C., USA, on 9 July, with a third event in Tokyo, Japan on July 10.
AMR is a looming global crisis that has the potential to dwarf COVID-19 in terms of deaths and economic costs.
Commenting on the Fund, Dr Tedros Adhanom Ghebreyesus, Director General World Health Organization, said: “AMR is a slow tsunami that threatens to undo a century of medical progress. I very much welcome this new engagement of the private sector in the development of urgently-needed antibacterial treatments. WHO looks forward to working with the AMR Action Fund to accelerate research to address this public health crisis.” New antibiotics The world urgently needs new antibiotics, but there are few in the pipeline because of a paradox: despite the huge societal costs of AMR, there is currently no viable market for new antibiotics. New antibiotics are used sparingly to preserve effectiveness, so in recent years, a number of antibiotic-focused biotechs have declared bankruptcy or exited this space due to the lack of commercial sustainability, resulting in the loss of valuable expertise and resources. The consequence is a huge public health need for new antibiotics, but a lack of funding available for antibiotic R&D, particularly the later stages of clinical research. This creates a “valley of death” between discovery and patient access.
“With the AMR Action Fund, the pharmaceutical industry is investing nearly US$1 billion to sustain an antibiotic pipeline that is on the verge of collapse, a potentially devastating situation that could affect millions of people around the world,” said David Ricks, Chairman and CEO of Eli Lilly and Company and President of IFPMA. “The AMR Action Fund will support innovative antibiotic candidates through the most challenging later stages of drug development, ultimately providing governments time to make the necessary policy reforms to enable a sustainable antibiotic pipeline.”
With this investment, the AMR Action Fund will be the largest collective venture ever created to address AMR. The AMR Action Fund will:
Invest in smaller biotech companies focused on developing innovative antibacterial treatments that address the highest priority public health needs, make a significant difference in clinical practice, and save lives.
Provide technical support to portfolio companies, giving them access to the deep expertise and resources of large biopharmaceutical companies, to strengthen antibiotic development, and support access and appropriate use of antibiotics.
Bring together a broad alliance of industry and non-industry stakeholders, including philanthropies, development banks, and multilateral organizations, and help encourage governments to create market conditions that enable sustainable investment in the antibiotic pipeline.
The Fund is expected to be operational during the fourth quarter of 2020.
For more details on the AMR Action fund, visit www.AMRactionfund.com
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:35:292020-08-26 14:35:31Biopharma companies invest $1bn in new AMR Action Fund to save collapsing antibiotic research pipeline
We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.
Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.
Essential Website Cookies
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.
We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.
We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.
.
Google Analytics Cookies
These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.
If you do not want us to track your visit to our site, you can disable this in your browser here:
.
Other external services
We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page
Google Webfont Settings:
Google Maps Settings:
Google reCaptcha settings:
Vimeo and Youtube videos embedding:
.
Privacy Beleid
U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.